Johnson & Johnson Announces Strategic Deal and Acquisition Option for Sail Biomedicines
Johnson & Johnson (JNJ) has entered into an agreement with Sail Biomedicines to advance in vivo CAR-T therapies targeting immune-mediated diseases. As part of the deal, J&J holds a $2.58 billion option to acquire Sail and will make initial payments totaling $785 million, including a $465 million equity investment. The partnership aims to accelerate research into innovative cell therapy approaches for conditions such as autoimmune disorders. This move aligns with Johnson & Johnson's broader strategy in the biotech sector, particularly within its Janssen Pharmaceuticals division focused on immunology and oncology.
Tickers: $JNJ
Topics: Biotech CAR-T Therapies Pharmaceuticals